Ustekinumab, sold under the brand name Stelara among others, is a monoclonal antibody medication developed by Janssen Pharmaceuticals, for the treatment...
25 KB (1,949 words) - 06:27, 13 June 2024
program comprising four clinical trials which compared risankizumab to ustekinumab, adalimumab and placebo in the indication of plaque psoriasis. The results...
13 KB (969 words) - 19:29, 20 December 2023
treatment with ustekinumab. It showed that patients who switched to guselkumab from ustekinumab did better than those who remained on ustekinumab. "Tremfya...
14 KB (1,017 words) - 04:34, 12 May 2024
share a common domain, p40, which is the target of the FDA-approved ustekinumab. In 2017 the US FDA approved guselkumab for plaque psoriasis. There have...
115 KB (12,976 words) - 18:32, 9 June 2024
disease ulcerative colitis ankylosing spondylitis inhibits TNF-α human ustekinumab Crohn's disease ulcerative colitis plaque psoriasis psoriatic arthritis...
47 KB (4,798 words) - 06:45, 26 May 2024
antibodies, such as infliximab, adalimumab, certolizumab, vedolizumab, ustekinumab, natalizumab,risankizumab-rzaa, and upadacitinib Hydrocortisone should...
159 KB (18,224 words) - 18:42, 8 June 2024
IL-12 Agonists: Edodekin alfa Interleukin 12 Antibodies: Briakinumab Ustekinumab IL-13 Agonists: Binetrakin Cintredekin besudotox Interleukin 4 Interleukin...
22 KB (1,841 words) - 22:50, 30 April 2024
and Th17 T-cells. IL-12 and IL-23 signaling is blocked by the biologic ustekinumab and IL-23 is blocked by guselkumab, mirikizumab and risankizumab, medications...
141 KB (16,072 words) - 23:23, 16 May 2024
certolizumab pegol and adalimumab, as well as the IL-12/IL-23 inhibitor ustekinumab, the IL-17A inhibitor secukinumab, and the IL-23 inhibitor risankizumab...
32 KB (3,436 words) - 07:19, 11 June 2024
history, preferences, and the recommendations of the healthcare provider. Ustekinumab has frequently been used as a second-line therapy for AS, but it has...
56 KB (5,960 words) - 20:25, 28 May 2024
Urtoxazumab mab humanized Escherichia coli diarrhoea caused by E. coli Ustekinumab Stelara mab human IL-12, IL-23 Y multiple sclerosis, psoriasis, psoriatic...
135 KB (4,013 words) - 03:57, 1 June 2024
received marketing authorization in 2021, and its second product, an ustekinumab biosimilar, in 2023. Products under development include biosimilars of...
11 KB (914 words) - 22:12, 28 November 2023
1 9.9 3 etanercept rheumatoid arthritis Enbrel 7.2 7.6 7.9 8.0 8.1 4 ustekinumab psoriasis Stelara 2.0 2.6 3.7 5.0 6.6 5 pembrolizumab oncology Keytruda...
29 KB (281 words) - 04:19, 27 November 2023
Armando; Moreira, Ana Isabel (2016-05-24). "Inverse psoriasis treated with ustekinumab". BMJ Case Reports. BMJ: bcr2016215019. doi:10.1136/bcr-2016-215019....
7 KB (611 words) - 16:36, 7 April 2024
IL-12 Agonists: Edodekin alfa Interleukin 12 Antibodies: Briakinumab Ustekinumab IL-13 Agonists: Binetrakin Cintredekin besudotox Interleukin 4 Interleukin...
15 KB (1,152 words) - 17:23, 8 June 2024
such as vedolizumab and natalizumab and interleukin antagonists like ustekinumab. Prior to the development of biological therapy as a modality to treat...
28 KB (3,343 words) - 13:52, 22 March 2024
Management of Crohn's disease (section Ustekinumab)
needed] Ustekinumab (CNTO 1275) is a monoclonal antibody that suppresses cytokines IL-12 and IL-23. Originally designed to treat psoriasis, ustekinumab was...
44 KB (4,607 words) - 00:50, 4 May 2024
factors csDMARD tocilizumab IL-6 receptor antagonist bDMARD tofacitinib Janus kinase (JAK) inhibitor tsDMARD ustekinumab IL-12 and IL-23 inhibitor bDMARD...
9 KB (835 words) - 03:16, 15 February 2024
tocilizumab-bavi/Tofidence tocilizumab/Actemra October 2023 ustekinumab-auub/Wezlana ustekinumab/Stelara December 2023 bevacizumab-tnjn/Avzivi bevacizumab/Avastin...
95 KB (6,480 words) - 22:51, 13 May 2024
IL-12 Agonists: Edodekin alfa Interleukin 12 Antibodies: Briakinumab Ustekinumab IL-13 Agonists: Binetrakin Cintredekin besudotox Interleukin 4 Interleukin...
24 KB (2,070 words) - 07:13, 15 March 2024
IL-12 Agonists: Edodekin alfa Interleukin 12 Antibodies: Briakinumab Ustekinumab IL-13 Agonists: Binetrakin Cintredekin besudotox Interleukin 4 Interleukin...
26 KB (3,305 words) - 06:50, 28 March 2024
Tocilizumab Ustekinumab Interleukin 5 Mepolizumab Immunoglobulin E Omalizumab Interferon Faralimomab IL-6 Elsilimomab IL-12 and IL-23 Lebrikizumab Ustekinumab IL-17A...
7 KB (299 words) - 13:45, 27 April 2024
bimekizumab is superior to not only adalimumab but also secukinumab and ustekinumab for the treatment of plaque psoriasis. "Bimzelx APMDS". Therapeutic Goods...
11 KB (668 words) - 07:03, 1 April 2024
IL-12 Agonists: Edodekin alfa Interleukin 12 Antibodies: Briakinumab Ustekinumab IL-13 Agonists: Binetrakin Cintredekin besudotox Interleukin 4 Interleukin...
22 KB (2,577 words) - 07:34, 3 June 2024
adenocarcinoma 761074 Link ustekinumab Stelara Centocor 9/25/2009 subcutaneous fully human IL12 IL23 Plaque psoriasis 125261 Link ustekinumab Stelara Janssen Biotech...
57 KB (4,064 words) - 10:19, 7 June 2024
23. This was what motivated researches to look at the viability of ustekinumab, a monoclonal antibody targeted against interleukin 12 and 23. An experiment...
112 KB (12,671 words) - 02:27, 18 March 2024
breast cancer humanized monoclonal antibody HER2/neu (erbB2) antagonist ustekinumab Stelara psoriatic arthritis, psoriasis, ulcerative colitis, Crohn's disease...
30 KB (2,882 words) - 04:07, 12 June 2024
IL-12 Agonists: Edodekin alfa Interleukin 12 Antibodies: Briakinumab Ustekinumab IL-13 Agonists: Binetrakin Cintredekin besudotox Interleukin 4 Interleukin...
16 KB (1,451 words) - 21:00, 23 April 2024
is one of the therapeutic targets to treat the inflammatory diseases. Ustekinumab, a monoclonal antibody directed against this cytokine, is used to treat...
20 KB (2,192 words) - 23:02, 27 November 2023
results for brodalumab in a Phase III trial comparing the compound with ustekinumab and a placebo in treating psoriasis. 2014: In November, construction...
97 KB (7,882 words) - 18:47, 29 May 2024